Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Daiichi-Sankyo
>
Daiichi to buy Accumetrics?
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3734795"]<b>Accumetrics is in deep trouble</b></p><p><br /></p><p>Coming back from the AHA, my feeling is this company is in deep trouble: </p><p><br /></p><p>- the technology: no significant predictivity in both multicenter studies performed: IMO people underestimate that this is the really sad message of the GRAVITAS data, even worse than the lack of benefit in the high clopidogrel group. See slide 19 in: <a href="http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf" rel="nofollow">http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf</a></p><p>And also slide 28 in:</p><p><a href="http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989" rel="nofollow">http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989</a></p><p>Failure to show any significant predictivity in two multi-center studies with 1001 patients (Verifrenchy) and 1691 patients (Gravitas observational substudy) means that the technology is not able to do what it is supposed to do: to identify patients at significantly increased risk. </p><p><br /></p><p>- the management: The accumetrics management seems to suffer from an inverse Midas syndrome: everything they do seems to fail. Also you meet all the time people that have negative stories about them to tell (or posts in this and other forums), and nobody who seems to be positive about them - obviously except from the investors. </p><p><br /></p><p>- financial data: 05-2003: series A financing $1.3 million, 07-2004: series B financing $13.5 million, 02-2006: series C financing $8.25 million, 02-2008: series D financing $28.8 million, 10-2009: series E financing $16.6 million, additional $7 million announced in 9-2010. </p><p>$75.5 million in VC??? </p><p>Is this a company or a Ponzi scheme? </p><p>$52.4 million since 2008, which is approximatelly $1.5 million per MONTH. </p><p>They don´t need a buyer, they need a bailout IMO. Perhaps Obama can help.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3734795"][b]Accumetrics is in deep trouble[/b] Coming back from the AHA, my feeling is this company is in deep trouble: - the technology: no significant predictivity in both multicenter studies performed: IMO people underestimate that this is the really sad message of the GRAVITAS data, even worse than the lack of benefit in the high clopidogrel group. See slide 19 in: [url]http://sciencenews.myamericanheart.org/pdfs/GRAVITAS_pslides.pdf[/url] And also slide 28 in: [url]http://spo.escardio.org/eslides/view.aspx?eevtid=33&fp=4989[/url] Failure to show any significant predictivity in two multi-center studies with 1001 patients (Verifrenchy) and 1691 patients (Gravitas observational substudy) means that the technology is not able to do what it is supposed to do: to identify patients at significantly increased risk. - the management: The accumetrics management seems to suffer from an inverse Midas syndrome: everything they do seems to fail. Also you meet all the time people that have negative stories about them to tell (or posts in this and other forums), and nobody who seems to be positive about them - obviously except from the investors. - financial data: 05-2003: series A financing $1.3 million, 07-2004: series B financing $13.5 million, 02-2006: series C financing $8.25 million, 02-2008: series D financing $28.8 million, 10-2009: series E financing $16.6 million, additional $7 million announced in 9-2010. $75.5 million in VC??? Is this a company or a Ponzi scheme? $52.4 million since 2008, which is approximatelly $1.5 million per MONTH. They don´t need a buyer, they need a bailout IMO. Perhaps Obama can help.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Daiichi-Sankyo
>
Daiichi to buy Accumetrics?
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Daiichi-Sankyo
>
Daiichi to buy Accumetrics?
>